Doxorubicin-Induced Mitochondrial Cardiomyopathy

作者: Kendall B. Wallace

DOI: 10.1007/0-306-46835-2_25

关键词: PolymeraseAnthracyclineDNA replicationDNADoxorubicinMolecular biologyCell cycleStreptomyces peucetiusTopoisomeraseChemistry

摘要: Doxorubicin is one of several water-soluble anthracenedione glycoside antibiotics produced by and originally isolated from Streptomyces peucetius var. caesius (Arcamone et al., U.S. patent 3,590,028, 1971, Farmitalia). The molecule consists a highly hydroxylated planar tetracycline quinone that glycosylated to characteristic duanosamine sugar residue. Mild acid hydrolysis yields the amino waterinsoluble biologically active aglycone, which are easily separated thin-layer or reversephase liquid chromatography. structure doxorubicin illustrated in Figure 1. most widely prescribed antineoplastic agents United States, mostly because its potent, broad-spectrum activity against both solid tumors leukemias. It particularly useful causing regression disseminated neoplasms, such as lymphoblastic myeloblastic leukemias, neuroblastomas, bone marrow sarcomas, malignant lymphomas. also effective various carcinomas, including those breast, bladder, thyroid. therapeutic attributed intercalation anthracycline ring into DNA double helix, inhibits replication transcription interfering with reading fidelity RNA polymerases. Alternatively, cytostatic effect may reflect formation sequencespecific complexes susceptible cleavage topoisomerase II (Zunino Capranico, 1990). Regardless, DNA, RNA, protein synthesis all inhibited, might be expected, cells sensitive during S-phase cell cycle. At low doses proliferation proceeds at time death occurs.

参考文章(160)
Tamara Hirsch, Isabel Marzo, Guido Kroemer, Role of the Mitochondrial Permeability Transition Pore in Apoptosis Bioscience Reports. ,vol. 17, pp. 67- 76 ,(1997) , 10.1023/A:1027339418683
L. A. Manziuk, R. Buehner, R. Canetta, M. Hayat, E. Villa, A. C. Mayr, H. J. Senn, C. G. Gallagher, R. Heinz, P. L. Vigo, G. Bonadonna, G. R. Lenaz, R. Waldner, P. Ribaud, N. I. Perevodchikova, R. Castellani, K. Kolaric, C. Pollini, W. Mattsson, C. Praga, W. Ten Bokkel-Huyninck, G. Beretta, H. von Melchner, G. De Wasch, Adriamycin cardiotoxicity: a survey of 1273 patients Cancer treatment reports. ,vol. 63, pp. 827- 834 ,(1979)
F. Piccinini, E. Monti, L. Paracchini, G. Perletti, Are Oxygen Radicals Responsible for the Acute Cardiotoxicity of Doxorubicin Advances in Experimental Medicine and Biology. ,vol. 264, pp. 349- 352 ,(1990) , 10.1007/978-1-4684-5730-8_54
P Steinherz, L Steinherz, Delayed cardiac toxicity from anthracycline therapy. Pediatrician. ,vol. 18, pp. 49- 52 ,(1991)
F Zunino, G Capranico, DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anti-cancer Drug Design. ,vol. 5, pp. 307- 317 ,(1990)
William McGuire, Emmanuel Saltiel, Doxorubicin (adriamycin) cardiomyopathy. Western Journal of Medicine. ,vol. 139, pp. 332- 341 ,(1983)
Patricia M. Sokolove, Roberta G. Shinaberry, Na+-independent release of Ca2+ from rat heart mitochondria. Induction by adriamycin aglycone. Biochemical Pharmacology. ,vol. 37, pp. 803- 812 ,(1988) , 10.1016/0006-2952(88)90165-7
Thomas E. Gunter, Douglas E. Wingrove, Srabani Banerjee, Karlene K. Gunter, Mechanisms of mitochondrial calcium transport. Advances in Experimental Medicine and Biology. ,vol. 232, pp. 1- 14 ,(1988) , 10.1007/978-1-4757-0007-7_1
L. E. Ainger, J. Ito, J. Bushore, W. W. Johnson, Daunomycin: a cardiotoxic agent. Journal of The National Medical Association. ,vol. 63, pp. 261- ,(1971)